Related Experiment Videos
Depletion of alloreactive donor T cells using immunomagnetic cell selection
1Bone Marrow Transplantation, University Hospital Eppendorf, Hamburg, Germany.
Bone Marrow Transplantation
|August 10, 2000
Summary
Researchers developed a new method to remove harmful alloreactive T cells from donor cells. This technique reduces the risk of graft-versus-host disease (GVHD) after bone marrow transplants and improves immunotherapy.
Area of Science:
- Immunology
- Transplantation Immunology
- Cell Therapy
Background:
- Donor T cells are crucial for engraftment and immune reconstitution post-allogeneic bone marrow transplantation (BMT).
- Alloreactive T cells can cause graft-versus-host disease (GVHD), a life-threatening complication, despite their anti-tumor effects (graft-versus-leukemia, GVL).
Purpose of the Study:
- To develop a strategy for selectively depleting alloreactive cells from donor leukocytes.
- To mitigate GVHD while preserving beneficial anti-tumor immunity in allogeneic BMT and adoptive immunotherapy.
Main Methods:
- Donor T cells were activated via co-cultivation with recipient stroma cells.
- Activation kinetics of CD3+, CD4+, and CD8+ T cells were analyzed.
- Magnetic cell sorting (MACS) was used to deplete cells expressing activation-induced antigens (CD25, CD69).
Main Results:
- Depletion of CD25- or CD69-positive cells significantly reduced donor T cell alloreactivity in vitro.
- Simultaneous depletion of both CD25- and CD69-positive cells resulted in the lowest level of alloreactivity.
- Depleted cell fractions retained reactivity against third-party cells, suggesting preserved beneficial immunity.
Conclusions:
- MACS-based ex vivo depletion of alloreactive cells is a promising strategy to prevent GVHD.
- This approach holds potential for improving outcomes in allogeneic BMT and adoptive immunotherapy.
- Selective T cell depletion offers a safer alternative for cell-based therapies.